Drug intelligence / Profile preview

sh3051

Development stage: Phase 1
Lead developer: Nanjing Sanhome Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

SH3051 is an orally bioavailable small molecule inhibitor targeting the serine/threonine kinase transforming growth factor-beta receptor 1 (TGF-βR1; also known as activin receptor-like kinase 5 or ALK5). It acts by inhibiting TGF-β signaling, which plays a key role in tumor progression and immune modulation. The drug is being developed primarily for antineoplastic (anticancer) and immunomodulating activities. Its main indications under investigation are advanced malignant solid neoplasms and liver cancer. The developer of SH3051 is Nanjing Sanhome Pharmaceutical.

Targets

TGFBR1

Beyond the preview

Go deeper on sh3051.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sh3051.

Explore the full profile